Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)

Primary Objective: To determine overall response rate (ORR) and to exclude that it is 20% or lower. Secondary Objectives: 1. To determine compliance and toxicity of the therapy. 2. To determine clinical benefit rate (CBR) in patients with measurable disease. 3. To determine duration of response. 4. To determine progression-free survival (PFS). 5. To determine overall survival. 6. To assess biomarkers, e.g. SPARC expression in the tissue of the primary or metastatic tumor.